title: Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study.
abstract: To determine whether specific antiplatelet therapies improved vein graft patency after coronary artery bypass grafting (CABG) we compared (1) aspirin, 325 mg daily, (2) aspirin, 325 mg three times daily, (3) aspirin plus dipyridamole (325 mg and 75 mg, respectively, three times daily), (4) sulfinpyrazone (267 mg three times daily), and (5) placebo (three times daily). Therapy, except aspirin, was started 48 hr before CABG. When aspirin was a treatment, one 325 mg dose was given 12 hr before surgery and therapy was maintained thereafter according to the assigned regimen. Angiographic graft patency data were obtained within 60 days of surgery. Analysis of early graft patency in 555 patients (1781 grafts), revealed the following graft patency rates: aspirin daily, 93.5%; aspirin three times daily, 92.3%; aspirin and dipyridamole, 91.9%; and sulfinpyrazone, 90.2%. All aspirin-containing therapeutic regimens improved (p less than .05) graft patency compared with placebo (85.2%). Chest tube drainage measured within the first 35 hr after CABG revealed that the median loss with aspirin daily (965 ml), aspirin three times daily (1175 ml), and aspirin plus dipyridamole (1000 ml) exceeded (p less than .02) that with placebo (805 ml), while median loss with sulfinpyrazone (775 ml) did not. The reoperation rate was greater (p less than .01) in all the treatment groups that received aspirin (6.5%) compared with the two nonaspirin groups (1.7%). Overall operative mortality was 2.3%, without significant differences among treatment groups. Transient renal insufficiency occurred in 5.3% of patients taking sulfinpyrazone. Thus, early vein graft patency was improved after CABG with all aspirin-containing drug regimens.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cooperative Studies Program of the Medical Research Service, Veterans Administration Central Office, Washington, D.C.
authors.forename: S
authors.initials: S
authors.lastname: Goldman
authors.forename: J
authors.initials: J
authors.lastname: Copeland
authors.forename: T
authors.initials: T
authors.lastname: Moritz
authors.forename: W
authors.initials: W
authors.lastname: Henderson
authors.forename: K
authors.initials: K
authors.lastname: Zadina
authors.forename: T
authors.initials: T
authors.lastname: Ovitt
authors.forename: J
authors.initials: J
authors.lastname: Doherty
authors.forename: R
authors.initials: R
authors.lastname: Read
authors.forename: E
authors.initials: E
authors.lastname: Chesler
authors.forename: Y
authors.initials: Y
authors.lastname: Sako
mesh_terms: D002986:Clinical Trials as Topic; D017023:Coronary Angiography; D001026:Coronary Artery Bypass; D004311:Double-Blind Method; D006083:Graft Occlusion, Vascular / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D012086:Reoperation; D012501:Saphenous Vein / Q000637:transplantation*; D013997:Time Factors; D014481:United States; D014493:United States Department of Veterans Affairs; D014654:Vascular Patency / Q000187:drug effects*
chemical_list: D010975:Platelet Aggregation Inhibitors